The Central Drugs Standard Control Organisation (CDSCO) has decided to waive local clinical trials for certain drugs approved in select ICH markets, expediting access to advanced therapies in India. This change aims to reduce delays and costs, making treatments like orphan drugs and gene therapies more accessible. The waiver applies under specific conditions, including no major safety issues and a commitment to post-marketing trials. This policy aligns India with global practices and addresses urgent healthcare needs. Read The Rest at :
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.
